other crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for “advanced biofuels is literally mm its infancy,” con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus’s technology 1s i

artnerships have been created on the potential of synthetic cannabinoid production. We highlight two such agreements from the past few months below. Amyris / Undisclosed Partner (February 2019; Valued Up to $255MM) In February 2019, Amyris announced that it has signed an agreement for cannabinoid develo

ulting in him crashing and falling off one of the vehicles. Complaint attached I Read full article » INTELLECTUAL PROPERTY Cannabinoid Maker Hits Amyris With $881M Trade Secrets Suit A cannabinoid manufacturer slapped biotech company Amyris with an $881 million trade secrets suit Thursday, alleging